Figure 10.

Inhibition AMPK signalling decreased the anti‐inflammatory ability of celastrol in activated HSCs. HSCs were transfected with AMPK1α siRNA or treatment with Compound C and then were treated with the indicated concentration of celastrol for 24 h. A‐C, ELISA measurement of IL‐1β, IL‐6 and IL‐18 levels in supernatant of HSCs treated with 20 µmol/L celastrol for 24 h following Compound C (10 µmol/L) treatment. D‐F, ELISA measurement of IL‐1β, IL‐6 and IL‐18 levels in supernatant of HSCs treated with 20 µmol/L celastrol for 24 h following AMPK1α siRNA treatment. Data are expressed as mean ± SD, and the experiments were repeated three times. Significance: ##P < .01 vs the control (DMSO) group; *P < .05 and **P < .01 vs the celastrol (20 μmol/L) alone treated group